Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors
Portfolio Pulse from
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. announced promising preliminary results from a Phase I clinical trial of pembrolizumab and LYMPHIR™ in cancer patients with recurrent solid tumors. The study showed a 27% Objective Response Rate and a 33% Clinical Benefit Rate, with a median Progression Free Survival of 57 weeks. The regimen was well-tolerated with no serious immune-related adverse events.
November 11, 2024 | 2:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citius Oncology, Inc. reported promising preliminary results from a Phase I trial for a cancer treatment regimen, indicating potential efficacy and safety.
The promising results from the Phase I trial could enhance the perceived value of Citius Oncology's research capabilities, potentially leading to a positive impact on CTOR's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Citius Pharmaceuticals, Inc. announced promising results from a Phase I trial for a cancer treatment regimen, showing significant efficacy and safety.
The positive preliminary results from the Phase I trial suggest potential efficacy and safety of the treatment regimen, which could boost investor confidence and positively impact CTXR's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90